Alteon Suspends Alagebrium Enrollment On Rat Toxicities Feb. 28, 2005 Alteon Inc. voluntarily suspended enrollment in its ongoing Phase II trials of alagebrium after preclinical data indicated high doses of the therapy could be associated with liver cell alterations and tumors. (BioWorld Today)Read More
Biotech - Big Pharma Collaborations: Modified And Terminated Agreements, Dec. 16, 2004-Feb. 23, 2005# Feb. 28, 2005
Manufacturing, Marketing And Distribution Agreements Between Biotech And Pharmaceutical Companies: Dec. 16, 2004-Feb. 23, 2005# Feb. 28, 2005
RSS